[1]孙 峰,鲍扬漪,朱 婷,等.晚期结直肠癌抗血管生成靶向治疗研究进展[J].医学信息,2019,32(17):1-4.[doi:10.3969/j.issn.1006-1959.2019.17.001]
　SUN Feng,BAO Yang-yi,ZHU Ting,et al.Advances in Anti-angiogenesis Targeted Therapy for Advanced Colorectal Cancer[J].Journal of Medical Information,2019,32(17):1-4.[doi:10.3969/j.issn.1006-1959.2019.17.001]
点击复制

晚期结直肠癌抗血管生成靶向治疗研究进展 ()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年17期
页码:
1-4
栏目:
出版日期:
2019-09-01

文章信息/Info

Title:
Advances in Anti-angiogenesis Targeted Therapy for Advanced Colorectal Cancer
文章编号:
1006-1959（2019）17-0001-04
作者:
孙 峰1; 鲍扬漪2; 朱 婷1; 李玉芝1
安徽医科大学第三附属医院/合肥市第一人民医院肿瘤内科1，血液肿瘤科2， 安徽 合肥 230061
Author(s):
SUN Feng1; BAO Yang-yi2; ZHU Ting1; LI Yu-zhi1
Department of Oncology1,Department of Hematology2,the Third Affiliated Hospital of Anhui Medical University/ Hefei First People's Hospital,Hefei 230061,Anhui,China
关键词:
血管生成; 靶向治疗; 血管内皮生长因子; 结直肠癌
Keywords:
Key words：Angiogenesis; Targeted therapy; Vascular endothelial growth factor; Colorectal cancer
分类号:
R735.3
DOI:
10.3969/j.issn.1006-1959.2019.17.001
文献标志码:
A
摘要:
结直肠癌是最常见的恶性肿瘤之一，大多数患者确诊时已属于晚期，姑息性化疗为主要的治疗手段，但单纯化疗有效率低，效果不理想，如何提高化疗效果则至关重要，靶向治疗在晚期结直肠癌的综合治疗模式中发挥着重要作用。结直肠癌是富含血管的肿瘤，血管生成对肿瘤的发生发展起着重要的作用，抗血管生成肿瘤治疗逐渐成为一种有前景的肿瘤治疗方法。血管内皮生长因子（VEGF）因其在血管生成过程中的关键作用成为了一个重要的治疗靶点。多种以VEGF及其通路为靶点的药物已经在临床中广泛用于晚期结直肠癌的治疗。本文就抗血管生成靶向药物在晚期结直肠癌靶向治疗中的研究进行综述。 关键词：血管生成；靶向治疗；血管内皮生长因子；结直肠癌
Abstract:
Abstract：Colorectal cancer is one of the most common malignant tumors. Most patients have advanced diagnosis at the time of diagnosis. Palliative chemotherapy is the main treatment. However, chemotherapy alone is inefficient and the effect is not satisfactory. How to improve the chemotherapy effect is crucial. Importantly, targeted therapy plays an important role in the comprehensive treatment of advanced colorectal cancer. Colorectal cancer is a tumor rich in blood vessels. Angiogenesis plays an important role in the development of tumors. Anti-angiogenic tumor therapy has gradually become a promising treatment for cancer. Vascular endothelial growth factor (VEGF) has become an important therapeutic target for its critical role in angiogenesis. A variety of drugs targeting VEGF and its pathway have been widely used in the treatment of advanced colorectal cancer in the clinic. This article reviews the progress of anti-angiogenic targeting drugs in the targeted therapy of advanced colorectal cancer.

参考文献/References:

[1]雷雨,于娇,何莉,等.沙利度胺联合XELOX方案治疗转移性结肠癌的预后效果及影响因素[J].解放军医药杂志,2018,30(10):23-26. [2]André T,Gramont AD,Vernerey D,et al.Adjuvant Fluorouracil,Leucovorin,and Oxaliplatin in Stage II to III Colon Cancer:Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study[J].J Clin Oncol,2015,33(35):4176-4187. [3]Beppu T,Emi Y,Tokunaga S,et al.Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab(KSCC0802Study)[J].Anticancer Res,2014,34(11):6655-6662． [4]张志红.贝伐单抗联合化疗晚期结直肠癌的效果研究[J].中国生化药物杂志,2017,37(9):131-132. [5]谢永铮,任学群.贝伐珠单抗联合FOLFOX治疗晚期转移性结直肠癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(22):2208-2210. [6]Fuchs CS,Fakih M,Schwartzberg L,et al.TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer:A randomized phase 1b/2 trial[J].Cancer,2013,119(24):4290-4298. [7]记荣佳,管凯,庄建发,等.贝伐珠单抗联合化疗治疗晚期大肠癌的疗效和安全性的meta分析[J].海军医学杂志,2018,11(39)6:526-544. [8]Canavese M,Ngo DT,Maddern GJ,et al.Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer[J].Int J Cancer,2017,140(10):2183-2191. [9]Ma WW, Xie H, Fetterly G,et al.A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients[J].American Journal of Clinical Oncology,2019,42(2):184-189. [10]Heinemann V,von Weikersthal LF,Decker T,et al.FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-linetreatment for patients with metastatic colorectal cancer(FIRE-3)：a randomised,open-label,phase 3 trial[J].Lancet Oncol,2014,15(10):1065-1075. [11]Giantonio BJ,Catalano PJ,Meropol NJ,et al.Bevacizumab in combination with oxaliplatin,fluorouracil,and leucovorin(FOLFOX4)for previously treated metastatic colorectal cancer:results from the Eastern Cooperative Oncology Group Study E3200[J].J Clin Oncol,2007,25(12):1539-1544. [12]Bennouna J,Sastre J,Arnold D,et al.Continuation of bevacizumab after first progression in metastatic colorectal cancer(ML18147):a randomised phase 3 trial[J].Lancet Oncol,2013,14(1):29-37. [13]Masi G,Salvatore L,Boni L,et al.Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer：final results of the ran-domized BEBYP trial[J].Ann Oncol,2015,26(4):724-730. [14]Diaz-Rubio E,Gomez-Espana A,Abad A,et al.Fist-line XELOX plus bevacizumab or single-agent bevacizumab as maintenmance therepy in patients with melastatic colorectal cancer:the phase III MACRO TTD study[J].Oncologist,2012,17(1):15-25. [15]Simkens LH,van Tinteen H,May A,et al.Maintenance treatment with capecitabine and bevacizumab in Metastatic colorectal cancer(CAIRO3):a phase 3 randomized controlled tial of the Dutch Coloretal Cancer Group[J].Lancet,2015,385(9980):1843-1852. [16]Hegewisch-Becker S,Graeven U,Lerchenmüller CA,et al.Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer(AIO 0207):a randomised,non-inferiority,open-label,phase 3 trial[J].Lancet Oncol,2015,16(13):1355-1369. [17]Koeberle D,Betticher DC,von Moos R,et al.Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastat ic colorectal cancer:a randomized phase Ⅲ non-inferiority trial(SAKK 41/06)[J].Ann Oncol,2015,26(4):709-714. [18]Tournigand C,Chibaudel B,Samson B.Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer(GERCOR DREAM;OPTIMOX3):a randomised,open-label,phase 3 trial[J].Lancet Oncol,2015,6(15):1493-1505. [19]Allegra CJ,Yothers G.Bevacizumab in stage Ⅱ-Ⅲ colon cancer5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial[J].J Clin Oncol,2013,31(3):359-364. [20]De Gramont A,Van Cutsem E,Schmoll HJ,et al.Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer(AVANT):a phase 3 randomised controlled trial[J].Lancet Oncol,2012,13(12):1225-1233. [21]Van Cutsem E,Prenen H,D'Haens G,et al.A phase Ⅰ/Ⅱ,open-label,randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic,colorectal cancer patients[J].Ann Oncol,2015,26(10):2085-2091. [22]Ranpura V,Hapani S,Wu S.Treatment-related mortality with bevacizumab in cancer patients：a meta-analysis[J].JAMA,2011,305(5):487-494. [23]Van Cutsem E,TabemeroJ,Lakomy R,et al.Additionof aflibercept to fluorouracil,leucovorin,an d irinotecan improves survival in aphaseⅢrandomized tril in patients with metastatic colorectal cancer previously treated with anoxaliplatin-based regimen[J].J Clin Oncol,2012,30(28):3499-3506. [24]Grothey A,Van Cutsem E,Sobrero A,et al.Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT):aninternational, multicentre,randomised,placebo-controlled,phase 3 trial[J].Lancet,2013,381(9863):303-312. [25]Li W,Zhao X,Du B,et al.Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy[J].Sci Rep,2016(6):30619. [26]何朗,孙永红,蒋莉,等.rh-Endostatin与肿瘤血管正常化时相的关系初探[J].中华肿瘤防治杂志,2016,23(19):1291-1297. [27]Wang J,Xiao J,Wei X,et al.Circulating endothelial cells and tumor blood volume as predictors in lung cancer[J].Cancer Sci,2013,104(4):445-452. [28]潘永勤,焦根龙.恩度联合化疗治疗晚期结直肠癌的近期疗效的Meta分析[J].南方医科大学学报.2014,34(2):270-274. [29]Li L,Huang XE.Thalidomide combined with chemotherapy in treating patients with advanced lung cancer[J].Asian Pac J Cancer Prev,2016,17(5):2583-2585.

相似文献/References:

[1]张文婧,宋 冰.HER-2阳性乳腺癌分子靶向治疗进展[J].医学信息,2018,31(24):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
　ZHANG Wen-jing,SONG Bing.Progress in Molecular Targeted Therapy for HER-2 Positive Breast Cancer[J].Journal of Medical Information,2018,31(17):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
[2]牛 悦,白建平,卢建跃.HER-2阳性胃癌的研究进展[J].医学信息,2019,32(01):44.[doi:10.3969/j.issn.1006-1959.2019.01.015]
　NIU Yue,BAI Jian-ping,LU Jian-yue.Progress in Research of HER-2 Positive Gastric Cancer[J].Journal of Medical Information,2019,32(17):44.[doi:10.3969/j.issn.1006-1959.2019.01.015]
[3]陈 旸,曾 川,张献全.肝细胞肝癌的靶向及免疫治疗研究现状与进展[J].医学信息,2019,32(03):45.[doi:10.3969/j.issn.1006-1959.2019.03.015]
　CHEN Yang,ZENG Chuan,ZHANG Xian-quan.Current Status and Progress of Research on Hepatocellular Carcinoma Targeting and Immunotherapy[J].Journal of Medical Information,2019,32(17):45.[doi:10.3969/j.issn.1006-1959.2019.03.015]
[4]杨珑静,马洪波,张献全.抗血管生成药物在非小细胞肺癌中的应用及研究进展[J].医学信息,2019,32(08):58.[doi:10.3969/j.issn.1006-1959.2019.08.018]
　YANG Long-jing,MA Hong-bo,ZHANG Xian-quan.Application and Research Progress of Anti-angiogenic Drugs in Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(17):58.[doi:10.3969/j.issn.1006-1959.2019.08.018]
[5]舒 旭,蒋 婷,李姿萱.HMGB1与胃癌组织血管形成的关系及其临床意义[J].医学信息,2019,32(15):77.[doi:10.3969/j.issn.1006-1959.2019.15.024]
　SHU Xu,JIANG Ting,LI Zi-xuan.Relationship between HMGB1 and Angiogenesis in Gastric Carcinoma and its Clinical Significance[J].Journal of Medical Information,2019,32(17):77.[doi:10.3969/j.issn.1006-1959.2019.15.024]
[6]唐武兵,杨 文,陈健智,等.尼妥珠单抗联合调强适形放疗及化疗治疗局部晚期肺鳞癌的研究[J].医学信息,2019,32(20):1.[doi:10.3969/j.issn.1006-1959.2019.20.001]
　TANG Wu-bing,YANG Wen,CHEN Jian-zhi,et al.Study of Nimotuzumab Combined with Intensity-modulated Radiotherapy and Chemotherapy in the Treatment of Locally Advanced Lung Squamous Cell Carcinoma[J].Journal of Medical Information,2019,32(17):1.[doi:10.3969/j.issn.1006-1959.2019.20.001]
[7]秦天宇,王立春.椎管内肿瘤手术方式的研究[J].医学信息,2019,32(22):35.[doi:10.3969/j.issn.1006-1959.2019.22.012]
　QIN Tian-yu,WANG Li-chun.Study on Surgical Methods of Intraspinal Tumor[J].Journal of Medical Information,2019,32(17):35.[doi:10.3969/j.issn.1006-1959.2019.22.012]
[8]李芮蝶,朱雪莉,陈 鑫.三阴乳腺癌分型与临床药物治疗的研究[J].医学信息,2020,33(05):40.[doi:10.3969/j.issn.1006-1959.2020.05.013]
　LI Rui-die,ZHU Xue-li,CHEN Xin.Study on the Classification of Triple Negative Breast Cancer and Clinical Drug Therapy[J].Journal of Medical Information,2020,33(17):40.[doi:10.3969/j.issn.1006-1959.2020.05.013]
[9]涂 强.lncRNAs在三阴性乳腺癌发生发展中的作用[J].医学信息,2020,33(10):37.[doi:10.3969/j.issn.1006-1959.2020.10.011]
　TU Qiang.The Role of lncRNAs in the Development of Triple Negative Breast Cancer[J].Journal of Medical Information,2020,33(17):37.[doi:10.3969/j.issn.1006-1959.2020.10.011]
[10]刘 垚,钱有辉.ctDNA检测及靶向药物在非小细胞肺癌中的应用[J].医学信息,2020,33(11):38.[doi:10.3969/j.issn.1006-1959.2020.11.013]
　LIU Yao,QIAN You-hui.Detection of ctDNA and Application of Targeted Drugs in Non-small Cell Lung Cancer[J].Journal of Medical Information,2020,33(17):38.[doi:10.3969/j.issn.1006-1959.2020.11.013]

更新日期/Last Update: 2019-09-01